Emetogenic potential of single oral antineoplastic agents^*

High/moderate
Abemaciclib Adagrasib Avapritinib Bosutinib Cabozantinib Ceritinib Crizotinib Cyclophosphamide Enasidenib Fedratinib Hexamethylmelamine Imatinib	Lenvatinib Lomustine Midostaurin Mobocertinib Niraparib Olaparib Procarbazine Ribociclib Rucaparib Selinexor^¶ Temozolomide Vinorelbine
Low/minimal
Acalabrutinib Afatinib Alectinib Alpelisib Apalutamide Asciminib Axitinib Bexarotene Brigatinib Capecitabine Capmatinib Chlorambucil Cobimetinib Dabrafenib Dacomitinib Darolutamide Dasatinib Duvelisib Encorafenib Entrectinib Erdafitinib Erlotinib Estramustine Etoposide Everolimus Fludarabine Futibatinib Gefitinib Gilteritinib Glasdegib Hydroxyurea Ibrutinib Idelalisib Infigratinib Ivosidenib Ixazomib Lapatinib Larotrectinib Lenalidomide Lorlatinib Melphalan (L-Phenylalanine mustard)	Methotrexate Neratinib Nilotinib Nintedanib Olutasidenib Osimertinib Palbociclib Panobinostat Pazopanib Pemigatinib Pexidartinib Pomalidomide Ponatinib Pralsetinib Regorafenib Relugolix Ripretinib Ruxolitinib Selpercatinib Sonidegib Sorafenib Sotorasib Sunitinib Talazoparib Tazemetostat Tegafur/uracil Tepotinib Thalidomide Tioguanin (6-thioguanine) Tivozanib Topotecan Trametinib Trifluridine/tipiracil Tucatinib Umbralisib Vandetanib Vemurafenib Venetoclax Vismodegib Vorinostat Zanubrutinib

* Classified emetic potential of oral agents based upon a full course of therapy and not a single dose within the first cycle.

¶ Emetic potential appears to be at the high end of the moderate category.

From: Jordan K, Chan A, Gralla RJ, et al. Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents—updated MASCC/ESMO consensus recommendation. Support Care Cancer 2023; 32:53. Copyright © 2023 The Authors. Available at: https://link.springer.com/article/10.1007/s00520-023-08220-5 (Accessed on April 11, 2024). Reproduced under the terms of the Creative Commons Attribution License 4.0.

Graphic 144747 Version 1.0

Buy a Package

Emetogenic potential of single oral antineoplastic agents*

Emetogenic potential of single oral antineoplastic agents^*